US EditionPerfuse Therapeutics announces positive results from phase 1/2a trial of PER-001, an intravitreal implant for glaucoma
Summary by ophthalmologytimes.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
All
Left
Center
Right
ARVO 2025: Perfuse Therapeutics announces positive results from phase 1/2a trial of PER-001, an intravitreal implant for glaucoma
The first-in-class endothelin antagonist intravitreal implant aided in increasing ocular blood flow and improved both visual function and anatomic structure, according to the company.
Perfuse Therapeutics Announces Positive Results from Phase 1/2a Trial of PER-001 Intravitreal Implant in Patients with Glaucoma
Perfuse Therapeutics announced positive 24-week results from its completed phase 1/2a trial of PER-001, a first in class endothelin antagonist intravitreal implant for glaucoma. Steven Mansberger, MD, MPH, Chief of Ophthalmology and Director of Glaucoma Services at Legacy Devers Eye Institute, and an investigator in the study, shared the results in an oral presentation at the Association for Research in Vision and Ophthalmology (ARVO) meeting. D…
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
